Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2024.04.017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Sudha S Shankar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland; Translational S…. Hauptthemen laut MEDLINE: Incretins. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Novartis, AstraZeneca.
Abstract (Originalsprache)
BACKGROUND & AIMS: Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, has demonstrated robust improvements in body weight, glycemia, and hepatic fat fraction (HFF) in patients living with obesity and type 2 diabetes mellitus. METHODS: In PROXYMO, a 19-week randomized double-blind placebo-controlled trial, the safety and efficacy of cotadutide (600 μg, 300 μg) or placebo were evaluated in 74 participants with biopsy-proven noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Analyses were performed using intent-to-treat and modified intent-to-treat population data. RESULTS: Dose- and time-dependent improvements in HFF, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), markers of liver health, and metabolic parameters were observed with significant improvements after 19 weeks with 600 μg ([least squares] mean difference vs placebo, [95% confidence interval] for absolute HFF: -5.0% [-8.5 to -1.5]; ALT: -23.5 U/L [-47.1 to -1.8]; AST: -16.8 U/L [-33.0 to -0.8]). Incidences of any grade treatment-emergent adverse events (TEAEs) were 91.7%, 76.9%, and 37.5% with cotadutide 600 μg, 300 μg, and placebo, respectively. The majority were gastrointestinal, mild to moderate in severity, and generally consistent with other incretins at this stage of development. TEAEs leading to treatment discontinuation were 16.7%, 7.7%, and 4.2% with cotadutide 600 μg, 300 μg, and placebo, respectively. CONCLUSIONS: PROXYMO provides preliminary evidence for the safety and efficacy of GLP-1/GCG receptor co-agonism in biopsy-proven noncirrhotic MASH with fibrosis, supporting further evaluation of this mechanism in MASH. CLINICAL TRIAL REGISTRATION NUMBER: NCT04019561.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland; Translational Science and Experimental Medicine, Research and Early Cardiovascular, R…
- Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
- Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gothenburg, Sweden.
- Global Patient Safety, Astra Zeneca, Gaithersburg, Maryland.
- Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
- Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Förderung
- Gilead Sciences
- Novartis
- AstraZeneca
Zitieren
APA
Shankar, S. S., Daniels, S. J., Robertson, D., Sarv, J., Sánchez, J., Carter, D., Jermutus, L., Challis, B., & Sanyal, A. J. (2024). Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.04.017
Vancouver
Shankar SS, Daniels SJ, Robertson D, Sarv J, Sánchez J, Carter D, et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2024.04.017
BibTeX
@article{Shankar2024,
author = {Shankar, Sudha S and Daniels, Samuel J and Robertson, Darren and Sarv, Janeli and Sánchez, José and Carter, Debra and Jermutus, Lutz and Challis, Benjamin and Sanyal, Arun J},
title = {Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2024.04.017}
}
EUVIMED